The CITYSCAPE trial, a phase II study evaluating the efficacy of tiragolumab plus atezolizumab in PD-L1-positive NSCLC, presented a significant ORR improvement (37% vs. 21%) as well as PFS improvement (5.6 vs. 3.9 months) for the combination group. The gene discussed is CD274; the disease is non-small cell lung carcinoma.